Jazz Pharmaceuticals plc announced that the US Drug Enforcement Agency has designated solriamfetol, also known as  Sunosi, as a Schedule IV medicine. The US Food and Drug Administration (FDA) approved Sunosi as the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

The once-daily medication will be available in the US in 75 mg and 150 mg tablets in July 2019. Learn more at this link.

We are always excited to hear about new medications that may help narcolepsy patients. We hope more research is being done and that our conversation with FDA representatives opened a door to a better understanding of this disorder and will lead to the development of more treatments.